Search research articles
Contact Us
Filters
Showing results (241-250 of 277) with videos related to
Page
of 28
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 13, 2020
Ivosidenib in Isocitrate Dehydrogenase 1<i>-</i>Mutated Advanced Glioma
Ingo K Mellinghoff, Benjamin M Ellingson, Mehdi Touat, et al.
Cancer Discovery
|
October 18, 2014
Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders
David M Hyman, Eli L Diamond, Cecile Rose T Vibat, et al.
Clinical Genitourinary Cancer
|
August 7, 2021
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials
Omar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
JCI Insight
|
April 20, 2017
First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients
Vivek Subbiah, Muhammad Rizwan Khawaja, David S Hong, et al.
Cancer Medicine
|
February 13, 2025
A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma
Omar Alhalabi, Mohamed A Gouda, Denái R Milton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 3, 2021
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial
Ingo K Mellinghoff, Marta Penas-Prado, Katherine B Peters, et al.
NPJ Precision Oncology
|
October 27, 2022
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology
Henry Hiep Vo, Siqing Fu, David S Hong, et al.
Oncotarget
|
May 19, 2015
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
Filip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Oncotarget
|
September 26, 2015
Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
Filip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Scientific Reports
|
August 23, 2022
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial
Tito R Mendoza, David S Hong, Christine B Peterson, et al.
Page
of 28
Search research articles
Search
Showing results (241-250 of 277) with videos related to
Sort By:
Page
of 28
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 13, 2020
Ivosidenib in Isocitrate Dehydrogenase 1<i>-</i>Mutated Advanced Glioma
Ingo K Mellinghoff, Benjamin M Ellingson, Mehdi Touat, et al.
Cancer Discovery
|
October 18, 2014
Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders
David M Hyman, Eli L Diamond, Cecile Rose T Vibat, et al.
Clinical Genitourinary Cancer
|
August 7, 2021
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials
Omar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
JCI Insight
|
April 20, 2017
First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients
Vivek Subbiah, Muhammad Rizwan Khawaja, David S Hong, et al.
Cancer Medicine
|
February 13, 2025
A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma
Omar Alhalabi, Mohamed A Gouda, Denái R Milton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 3, 2021
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial
Ingo K Mellinghoff, Marta Penas-Prado, Katherine B Peters, et al.
NPJ Precision Oncology
|
October 27, 2022
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology
Henry Hiep Vo, Siqing Fu, David S Hong, et al.
Oncotarget
|
May 19, 2015
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
Filip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Oncotarget
|
September 26, 2015
Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
Filip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Scientific Reports
|
August 23, 2022
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial
Tito R Mendoza, David S Hong, Christine B Peterson, et al.
Page
of 28